Transforming the treatment of fibrosis

New anti-fibrotic therapies based on breakthrough science

Our Mission

Fibrotic diseases are a major burden on human health, afflicting millions of people every year with few treatment options available.

Our mission is to create new anti-fibrotic therapies based on breakthrough science.

Pulmonary Fibrosis

Cardiomyopathy & Heart Failure

Atrial Fibrillation

Non-alcoholic Steatohepatitis

Chronic Kidney Disease

Inflammatory Bowel Disease

Scleroderma

We are developing first-in-class antibody therapeutics to treat fibrosis.

Our Focus

Human-based genetic & genomic discovery

Cutting edge human fibrosis assays

Excellent models of human disease

Strong human genetic data supporting drug safety

Our Products

Cytokine Antibody

Phage display based on a human naive antibody library

Receptor Antibody

Genetic immunisation of mice and antibody humanisation

Decoy Receptor

Soluble receptors to inhibit cytokine signalling

siRNA

Specific inhibition of signalling using siRNA technology

Integrated human discovery and efficacy screening pipelines for all our products.

Read More

null

null